Valuation: Royalty Pharma plc

Market Cap 28.44B 25.39B 23.46B 21.26B 39.77B 2,699B 40.43B 282B 112B 1,414B 107B 104B 4,459B P/E 2026 *
26x
P/E 2027 * 18.4x
Enterprise Value 37.43B 33.42B 30.88B 27.98B 52.35B 3,553B 53.22B 372B 147B 1,862B 140B 137B 5,869B EV / Sales 2026 *
10.7x
EV / Sales 2027 * 9.81x
Free-Float
72.42%
Yield 2026 *
1.58%
Yield 2027 * 1.69%
1 day+0.17%
1 week+4.76%
Current month+9.42%
1 month+10.77%
3 months+8.20%
6 months+28.65%
Current year+65.27%
1 week 60.04
Extreme 60.04
63.97
1 month 55.13
Extreme 55.13
63.97
Current year 38.29
Extreme 38.29
64.38
1 year 35.92
Extreme 35.915
64.38
3 years 24.05
Extreme 24.05
64.38
5 years 24.05
Extreme 24.05
64.38
10 years 24.05
Extreme 24.05
64.38
Manager TitleAgeSince
Chief Executive Officer 62 01/01/1996
Director of Finance/CFO 44 01/01/2010
Chief Tech/Sci/R&D Officer - 21/09/2023
Director TitleAgeSince
Chairman 62 01/04/2020
Director/Board Member 68 11/02/2020
Director/Board Member 63 16/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Sell

Executive/Senior Manager

-4,126 0.0009%
30/09/26 Free

Director

642 0.0001%
28/09/26 Sell

Executive/Senior Manager

-4,126 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+0.17%+4.76%+73.30%+133.24% 28.44B
-2.54%+1.31%+55.10%+120.84% 1,135B
-1.42%+3.23%+37.07%+74.26% 636B
+0.16%+0.08%+25.14%+97.36% 505B
-0.31%+3.09%+43.92%+64.55% 378B
-1.34%-0.47%+66.63%+40.56% 358B
-0.68%+2.65%+22.46%+51.48% 295B
-1.20%+3.04%+2.62%+26.97% 266B
-1.79%+1.57%+49.97%+60.87% 237B
-0.73%-0.10%+29.24%+101.19% 193B
Average -0.58%+2.43%+40.55%+77.13% 403.28B
Weighted average by Cap. -0.25%+2.68%+41.22%+82.49%

Financials

2026 *2027 *
Net sales 3.51B 3.13B 2.89B 2.62B 4.9B 333B 4.98B 34.8B 13.78B 174B 13.16B 12.88B 550B 3.82B 3.42B 3.16B 2.86B 5.35B 363B 5.44B 37.97B 15.03B 190B 14.35B 14.05B 600B
Net income 1.47B 1.31B 1.21B 1.1B 2.05B 139B 2.08B 14.54B 5.76B 72.87B 5.5B 5.38B 230B 1.77B 1.58B 1.46B 1.32B 2.48B 168B 2.52B 17.59B 6.96B 88.12B 6.65B 6.51B 278B
Net Debt 8.99B 8.03B 7.42B 6.72B 12.58B 854B 12.79B 89.28B 35.35B 447B 33.75B 33.03B 1,410B 9.1B 8.13B 7.51B 6.8B 12.73B 864B 12.94B 90.33B 35.76B 453B 34.15B 33.42B 1,427B
Projected Income Statement - Annual - Royalty Pharma plc
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and over 17 development-stage product candidates.
Employees
100
Date Price Change Volume
23/10/26 $63.86 +0.17% 4,015,551
22/10/26 $63.75 +2.57% 2,808,473
21/10/26 $62.15 -0.16% 2,742,110
20/10/26 $62.25 +3.29% 2,493,205
19/10/26 $60.27 -1.13% 2,813,226
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Royalty Pharma plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
63.86USD
Average target price
65.38USD
Spread / Average Target
+2.37%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Royalty Pharma plc
  1. Stock Market
  2. Stocks
  3. RPRX Stock